[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100519243":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":36,"centralContacts":40,"locations":46,"responsibleParty":64,"collaborators":66,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":10,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":83,"minAge":84,"maxAge":10,"enrollmentInfo":85,"targetDuration":10,"studyType":88,"phases":10,"briefSummary":89,"conditions":90,"keywords":10,"overallStatus":49,"whyStopped":10,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Qilu Hospital of Shandong University","OTHER",[8,13,16,19,22,25],{"label":9,"type":10,"description":10,"interventionNames":11},"Patients with PDAC",null,[12],"Diagnostic Test: Pancreatic elastase-1 in blood serum",{"label":14,"type":10,"description":10,"interventionNames":15},"Individuals at high risk for PDAC",[12],{"label":17,"type":10,"description":10,"interventionNames":18},"Group of neuroendocrine neoplasm of pancreas",[12],{"label":20,"type":10,"description":10,"interventionNames":21},"Group of solid pseudopapillary tumor of pancreas",[12],{"label":23,"type":10,"description":10,"interventionNames":24},"Group of abnormally elevated CA19-9",[12],{"label":26,"type":10,"description":10,"interventionNames":27},"Controls without pancreatic disease or elevated CA19-9",[12],[29],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DIAGNOSTIC_TEST","Pancreatic elastase-1 in blood serum","Serum samples were collected from each patient to detect serum multiomics and pancreatic elastase-1 (PE-1). We examine multiomics in the pancreatic tissue collected from the patient who had undergone surgery or the necessary puncture examination and signed the informed consent form.",[26,23,17,20,14,9],[35],"Multiomics in blood serum or tissue",[37],{"name":38,"affiliation":5,"role":39},"Ning Zhong, MD","PRINCIPAL_INVESTIGATOR",[41],{"name":42,"role":43,"phone":44,"phoneExt":10,"email":45},"Zhen Li, MD","CONTACT","18560086106","qilulizhen@sdu.edu.cn",[47],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Ning Zhong","RECRUITING","Jinan","Shandong","250063","China","CN",{"type":56,"coordinates":57},"Point",[58,59],116.99722,36.66833,{"lat":59,"lon":58},[62,63],{"name":38,"role":43,"phone":10,"phoneExt":10,"email":10},{"name":42,"role":43,"phone":44,"phoneExt":10,"email":45},{"type":65,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[67,69,71,73],{"name":68,"class":6},"First Affiliated Hospital, Sun Yat-Sen University",{"name":70,"class":6},"First Affiliated Hospital of Guangxi Medical University",{"name":72,"class":6},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"name":74,"class":6},"LanZhou University","100519243","pancreatic-cancer-screening-through-the-detection-of-elastase-1-combined-with-other-examinations-100519243",false,"NCT06041009","Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations","Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations: A Multicenter, Prospective, Diagnostic Clinical Cohort Study.","Inclusion Criteria:\n\nCase groups (matching any of the following):\n\n1. Patients with pancreatic cancer with recognized diagnostic criteria or conclusions.\n2. Patients who are the high-risk group of pancreatic cancer.\n3. Patients with solid pseudo papilloma and neuroendocrine tumors of pancreas with recognized diagnostic criteria or conclusions.\n4. Patients with other diseases with abnormally elevated CA19-9.\n\nControl group:\n\n(1) Patients without pancreatic disease assessed by laboratory tests and imaging examinations have no CA19-9 elevation.\n\nExclusion Criteria:\n\n1. Patients who are younger than 18 years of age.\n2. Patients with suspected pancreatic malignant lesions but has no confirmed imaging or pathological diagnosis.\n3. Patients who have not signed informed consent.",true,"ALL","18 Years",{"count":86,"type":87},2100,"ESTIMATED","OBSERVATIONAL","This is a prospective cohort study. The investigators enroll subjects with pancreatic ductal adenocarcinoma (PDAC), individuals at high risk for PDAC, patients with other pancreatic diseases, patients with CA19-9 elevation and controls without pancreatic disease. This study aims to establish a diagnostic prediction model by using elastase 1, common clinical serological examinations, and imaging examinations including endoscopic ultrasonography (EUS), and to explore the diagnostic ability of the model in the high-risk population of PDAC. Besides, the investigators search for new biomarkers by multi-omics studies of serum and pancreatic tissues to further improve the diagnostic performance of this model. In conclusion, this study seeks a robust diagnostic prediction model to diagnose PDAC, especially early resectable PDAC.",[91,92,93,94,95,96],"Pancreatic Ductal Adenocarcinoma","Pancreatic Diseases","Pancreatic Elastase 1","Pancreatic Neuroendocrine Tumor","Pancreatitis","Pancreatic Neoplasms","2024-10-16",{"date":99,"type":100},"2024-10-18","ACTUAL",{"date":102,"type":100},"2023-05-05",{"date":104,"type":87},"2025-09-30",{"name":5,"class":6},1]